Glycation of proteins forms fructosamines and AGEs (advanced glycation end products). Oxidative and nitrosative stress leads to the formation of oxidative and nitrosative modifications. The modified amino acid residues formed in these processes are biomarkers of protein damage: some are risk markers and some may be risk factors for disease development. We developed a method for the concurrent quantitative measurement of 16 biomarkers indicative of protein glycation, oxidation and nitrosation damage using LC-MS/MS (LC with tandem MS detection). Underivatized analytes were detected free in physiological fluids and in enzymatic hydrolysates of cellular and extracellular proteins. Hydroimidazolones were the most important glycation biomarkers, and methionine sulphoxide was the most important oxidative biomarker quantitatively; 3-nitrotyrosine was the biomarker of nitrosation. Quantitative screening showed high levels of AGEs in cellular protein and moderate levels in protein of blood plasma. Levels of 3-nitrotyrosine were typically 100-fold lower than this. The major glycation adducts in blood plasma had high renal clearances in normal healthy human subjects, whereas methionine sulphoxide and 3-nitrotyrosine had low renal clearances due to further metabolism. Physiological AGEs in blood plasma were eliminated from the circulation in the kidney and not in the liver. LC-MS/MS peptide mapping was also used to locate the protein biomarkers. These studies reveal that advanced glycation is a significant modification of cellular and extracellular protein. The enzymatic defences against glycation, antioxidants and proteasomal protein degradation inside cells are probable factors regulating biomarker levels of cellular protein.
Introduction
Glycation, oxidation and nitrosation of proteins have been implicated in disease mechanisms. There is substantial evidence linking protein glycation to the development of vascular complications of diabetes and uraemia, and with aging, with less well-established links to non-diabetic vascular disease, Alzheimer's disease and inflammatory disorders (reviewed in [1] ). Protein oxidation and nitrosation are also implicated in some of these diseases, as well as environmental chemicaland drug-induced toxicity [2, 3] . Glycation adducts are imidazolium salt]; MetSO, methionine sulphoxide; MetSO2, methionine sulphone; LC-MS/MS, LC with tandem MS detection; MG-H1, N δ -(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine; MG-H2, 5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-yl)norvaline; MG-H3, 5-(2-amino-4-hydro-4-methyl-5-imidazolon-1-yl)norvaline; MOLD, methylglyoxal-derived lysine dimer [1,3- di(N ε -lysino)-4-methylimidazolium salt]; MRM, multiple reaction monitoring; 3-NO2Tyr, 3-nitrotyrosine. 1 To whom correspondence should be addressed (e-mail thorp@essex.ac.uk).
formed by the reaction of proteins with glucose, reactive α-oxoaldehydes such as glyoxal, methylglyoxal and 3-deoxyglucosone, and other saccharide derivatives. The initial Schiff-base adducts formed from glucose and lysine and N-terminal amino acid residues rearrange slowly to form fructosamine residues. Schiff-base and fructosamine residues are called early glycation adducts. Fructosamine degradation and the direct reaction of α-oxoaldehydes with proteins form many AGEs (advanced glycation end products) (Figure 1 ). Protein oxidation biomarkers are formed by the reaction of peroxides, hypochlorite, oxidizing free radicals and haem iron species with susceptible amino acids, particularly methionine and tyrosine (studied herein), and cysteine thiols, tryptophan and histidine (not studied herein). The major protein nitrosation biomarker is 3-nitrotyrosine, formed by the reaction of tyrosine with peroxynitrite and chlorylnitrite [3] . Protein biomarkers are also present in food and are absorbed as free adducts after digestion [4] . Glycation reactions are increased in diabetes mellitus, where there is an increased plasma glucose concentration and also increased concentrations of glyoxal, methylglyoxal and 3-deoxyglucosone [5] [6] [7] . Oxidative reactions may be increased by oxidative stress arising from mitochondrial dysfunction, activation of NADPH oxidase, uncoupling of nitric oxide synthase [8, 9] , metabolism of environmental chemicals and drugs, and many other processes [10] . Protein nitrosation is increased in cellular-mediated immunity, vascular disorders, endotoxaemia and other diseases -particularly when there is high expression of inducible nitric oxide synthase [3] .
AGEs have a wide range of chemical stabilities, with half-lives from days to years under physiological conditions [11, 12] . They also have varied biological effects. Some AGEs are protein cross-links, e.g. the bis(lysyl)imidazolium salts GOLD {glyoxal-derived lysine dimer; 1, 3- 
, and pentosidine, and may thereby denature proteins, confer resistance to proteolysis and change cell-extracellular-matrix interactions. When AGEs are formed at critical sites in enzymes and other proteins, they are associated with enzyme inactivation and loss of physiological function -for example, methylglyoxal-derived AGEs in glycolytic enzymes and heat shock protein 27 [13, 14] . Since AGEs have distinctive precursors, stabilities and biological functions, only discrete AGE analyte measurement in a comprehensive survey of AGEs will give a complete insight into the glycation status of a protein. Further studies may then be performed to identify sites of individual glycation adducts and glycation-related changes in protein structure and function.
Oxidative biomarkers may be formed reversibly, e.g. protein cysteine residue oxidation to cystine residues with reduction back to cysteine by protein thiol transferases and GSH, and the oxidation of methionine to MetSO (methionine sulphoxide) with reduction back to methionine by methionine sulphoxide reductase. Proteins may also be oxidized and nitrosated irreversibly, e.g. the oxidation and nitrosation of tyrosine to dityrosine and 3-NO 2 Tyr (3-nitrotyrosine) respectively, and the oxidation of tryptophan to kynurenine derivatives [10] . † These analytes were assayed using the method with mobile phase of 0.1% (v/v) trifluoroacetic acid.
Quantitative screening of protein biomarkers by LC-MS/MS (LC with tandem MS detection) MRM (multiple reaction monitoring)
Quantitative screening of a comprehensive range of protein biomarkers, protein-localized and free, in cellular and extracellular proteins and body fluids was achieved using LC-MS/MS with internal standardization by stable isotopesubstituted standards. Free biomarkers were determined by analysis of analytes in the ultrafiltrate of physiological fluids (12 kDa cut-off filter). Protein biomarker residues were determined after delipidification and enzymatic hydrolysis of protein samples. The amount of protein required for the assay was 50 µg of protein equivalents. Samples were assayed by LC-MS/MS using a 2690 Separation module with a Quattro Ultima triple quadrupole mass spectrometric detector (Waters-Micromass, Manchester, U.K.) using two Hypercarb TM columns (Thermo Hypersil Ltd, Runcorn, U.K.) in series. Protein biomarkers were detected by electrospray positive ionization-mass spectrometric MRM with programmed molecular ion, and fragment ion masses and collision energies were optimized to ±0.1 Da and ±1 eV for MRM detection of analytes (Table 1) , as described in [15] . Retention of the analytes was required to enable the diversion of non-volatile salts to waste prior to analyte elution and to resolve isobaric interferences from the analytes. A twocolumn switching system facilitated the elution of hydrophobic analytes and column washing.
Hydroimidazolones were important AGEs quantitatively in proteins glycated in vitro [16] .
The epimer pairs of MG-H structural isomers, MG-H1 [N δ -(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine], MG-H2 [5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-yl)norvaline] and MG-H3 [5-(2-amino-4-hydro-4-methyl-5-imidazolon-1-yl)norvaline] [11]
, were partially resolved in the LC-MS/MS chromatogram, but the structural isomers co-eluted. The detector response to each isomer was similar, and MG-H determinations reflected the sum of all isomers, although MG-H1 is the major isomer formed in proteins modified minimally by low concentrations of methylglyoxal, as found in vivo. Analogous structural isomers of glyoxal-derived hydroimidazolones were also not resolved and gave one peak (R t = 24.9 min). Hydroimidazolones derived from 3DG-H (3-deoxyglucosone) were resolved into the three structural isomers, eluting in the order 3DG-H3 {5- [2- 2 Tyr, argpyrimidine and pentosidine was performed with a more acidic eluent to improve ionization and elution from the column.
LC-MS/MS measurement of 3-NO

Cellular and extracellular AGE-modified proteins
The concentrations of AGEs in protein of human blood cells and blood plasma in vivo, and human kidney mesangial cells after 4 days of culture in vitro, were determined. For all AGEs, the concentration of the AGE residue was higher in cellular protein than in plasma protein, e.g. CML (N ε -carboxymethyl-lysine): plasma protein, 0.021 mmol/ mol of Lys; cellular protein, 0.068-0.233 mmol/mol of Lys; MG-H1: plasma protein, 0.92 mmol/mol of Arg; cell protein, 1.22-7.46 mmol/mol of Arg. The concentration of fructosyllysine residues in cellular protein was higher or lower than in plasma protein: 0.017-1.74 compared with 0.767 mmol/mol of Lys. MetSO residues were present at similar concentrations in cellular and plasma protein: 0.81-2.59 and 2.83 mmol/mol of Met respectively. The protein cross-link pentosidine was found in low concentrations, as expected (0.0056-0.085 mmol/mol of Lys); the highest concentration was in neutrophils (0.085 mmol/mol of Lys). Bis(lysyl)imidazolium cross-link AGEs were not detectable, except for MOLD in plasma and red blood cells at 0.0008 and 0.0053 mmol/mol of Lys respectively.
Hydroimidazolone AGEs
The highest levels of AGE residues were found for the hydroimidazolones MG-H1 and 3DG-H. These AGEs accounted for 0.1-2% of total arginine residues. Hydroimidazolones were major AGEs in physiological proteins. They are AGEs of moderate stability with half-lives of 1-10 weeks under physiological conditions. The availability of the α-oxoaldehyde precursor and proteasomal degradation of AGE-modified proteins [17] are probable factors that influence the concentration of AGE residues in short-lived cellular proteins in vivo. The availability of the α-oxoaldehyde precursor, protein concentration and renal and tissue metabolism of plasma protein are probable factors that influence the concentration of AGE residues in plasma proteins in vivo. The cellular export of AGEs, the absorption of AGEs from food and AGE renal clearance are probable factors that influence the concentration of free AGEs in blood plasma in vivo.
Oxidative and nitrosative biomarkers
MetSO is an important oxidative modification of cellular protein. It may be reduced to methionine by cytosolic MetSO reductase or further oxidized to MetSO 2 (methionine sulphone) [18] (Figure 2) , although further oxidation is usually a slow process. Unless MetSO reductase activity is overcome by an overwhelming oxidative insult, the concentration of MetSO may change little; if overwhelming oxidative insult occurs, conversion of MetSO into MetSO 2 may decrease levels of MetSO. The concentration of MetSO, therefore, may not change in mild oxidative stress, and may decrease on severe oxidative stress. Dityrosine, an irreparable marker of oxidative damage to proteins, was only detected in red blood cells (0.35 ± 11 mmol/mol of Tyr). Haemoglobin appears to be particularly sensitive to dityrosine formation. This has been attributed to a readily oxidized tyrosine residue close to the haem moiety that forms dityrosine by intersubunit cross-linking [19] (Figure 2) .
Estimates of 3-NO 2 Tyr residues in plasma protein and of free 3-NO 2 Tyr in plasma (0.0018 ± 0.0014 mmol/mol of Tyr and 6.5 nM respectively) were similar to recent artifactfree estimates (e.g. [20] ). MetSO and 3-NO 2 Tyr both had low renal clearances (<10 ml/min). This reflects the efficient renal reduction of MetSO by MetSO reductase [18] and renal re-uptake and/or metabolism of 3-NO 2 Tyr [21] .
AGE residues in proteins and free in plasma, urinary AGEs, and renal and hepatic clearance
The presence of relatively high concentrations of AGEs in cellular proteins and the rapid turnover of these proteins suggests that free AGEs may be exported from cells to be excreted eventually in the urine. Indeed, AGEs are considered to be a class of uraemic toxin [22] . Free AGEs were found in blood plasma in the concentration range 0.8 nM (pentosidine) to 147 nM (3DG-H). This represented generally a minor proportion ( 6%) of total AGE moieties in blood plasma, except for MOLD and argpyrimidine. Most AGE moieties were normally present, therefore, as AGE residues in plasma protein. The AGEs found in highest concentrations in cellular and extracellular protein, when liberated as free AGEs, have high renal clearances, although there may be some reabsorption and/or renal tubular metabolism of hydroimidazolones. This indicates that there is efficient renal clearance of the major AGEs formed by protein glycation in physiological systems. We were unable to detect the presence of low-molecular-mass peptides enriched in AGEs (AGE peptides) in either normal controls or subjects with ESRD (end-stage renal disease). Previous estimates of AGEs in the low-molecular-mass fraction of plasma by immunoassay may have mistaken the extraordinarily marked changes of free AGEs in uraemia with the presence of AGE peptides.
The major fate of plasma protein AGEs has been claimed to be clearance in the liver [23] . We analysed AGE residues in plasma protein and free plasma AGEs in hepatic arterial and portal venous blood flow into the liver and hepatic venous blood flow out of the liver (in collaboration with Professor A. Heidland, University of Würzburg, Würzburg, Germany). We found no evidence for clearance of protein or free AGEs from the circulation in the liver, except for a small amount of protein MG-H1 residues.
Quantitative screening of AGEs and insights into the physiological glycation process
We have determined the concentrations of the major AGEs in physiological tissues and fluids, including initial assessment of changes in diabetes at sites of development of vascular complications, and in uraemia comparing the effects of peritoneal dialysis and haemodialysis therapy. The key new insights are: (i) AGEs are quantitatively important modifications of cellular and extracellular protein, particularly hydroimidazolones, in normal and abnormal physiological states; (ii) free AGEs are present in blood plasma with a relatively high renal clearance and accumulate markedly in ESRD, and (iii) the accumulation of AGEs in diabetes and uraemia is consistent with AGE formation contributing to vascular dysfunction in these disease states. For cellular protein, a probable key function of proteasomal processing of proteins is to clear these glycated and damaged proteins from physiological systems, with release of glycation adducts into the circulation and subsequent renal clearance. In this regard, CML-modified proteins were substrates for proteasomal degradation, but proteins modified by hydroimidazolones minimally have not been investigated -except that the native protein proteasomal degradation studied in previous work [17] probably contained hydroimidazolones. We can now appreciate that the cytosolic glyoxalase system and other enzymes (aldehyde reductases and dehydrogenases), in suppressing the cellular accumulation of α-oxoaldehydes, serve to protect cellular proteins from advanced glycation. Our studies show that the protection they afford is not complete, and may be overwhelmed in some conditionsparticularly in diabetes and ESRD [24] .
